Phase 3 IMpactMF Trial Evaluating Imetelstat in R/R Myelofibrosis Is Discontinued
Geron Corporation has discontinued its phase 3 IMpactMF trial for imetelstat (Rytelo) in relapsed/refractory myelofibrosis after an independent data monitoring committee suggested it was unlikely to meet the primary endpoint of overall survival. The trial enrolled 327 patients and was expected to complete in 2028. Geron plans to analyze the data and share findings later. Imetelstat is FDA-approved for certain myelodysplastic syndromes.
How this was made
The 30-second read
Why it matters
The discontinuation removes a potential new indication, likely triggering a sell‑off in the short term while the approved MDS label remains a revenue source.
Market read
Primary biotech news; first disclosure of a phase‑3 trial halt, material for investors.
What to watch
Geron's existing FDA‑approved imetelstat for MDS may sustain revenue; the trial halt does not affect that indication.
Background
Geron (NASDAQ: GERN) develops telomerase inhibitor imetelstat, recently approved for low‑ to intermediate‑1 risk myelodysplastic syndromes.
Ticker impact
Geron announced the discontinuation of its phase 3 IMpactMF trial of imetelstat for relapsed/refractory myelofibrosis.
downward pressure as investors price in the loss of a pivotal trial
Phase‑3 trial failure is material for a biotech; no new safety concerns but no future revenue from this indication.
Market effects
May dampen sentiment for myelofibrosis and broader hematology biotech peers.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche oncology investors.
Counterpoint
If the safety profile remains clean, the trial stop could free resources for other pipelines, offering a longer‑term upside.
Key entities
- CompanyGeron Corporation
Biopharma developing imetelstat.
- DrugImetelstat (Rytelo)
Telomerase inhibitor under investigation for myelofibrosis.
